Immunovant, INC. (IMVT) — SEC Filings

Overview

Immunovant, INC. (IMVT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 9, 2026: On April 9, 2026, Immunovant, Inc. filed a Form 4, reporting changes in beneficial ownership of securities. The report covers transactions that occurred on April 7, 2026. The filing was accepted by the SEC on April 9, 2026.

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 26 neutral. The dominant filing sentiment for Immunovant, INC. is neutral.

Filing Type Overview

Immunovant, INC. (IMVT) has filed 2 4, 15 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (29)

• Immunovant Files Form 4 for Ownership Changes — 4 · Apr 9, 2026 Risk: low
  On April 9, 2026, Immunovant, Inc. filed a Form 4, reporting changes in beneficial ownership of securities. The report covers transactions that occurred on Apri
• 4 Filing — 4 · Apr 9, 2026
• 8-K Filing — 8-K · Dec 12, 2025
• Immunovant Files 8-K: Unspecified Event Reported — 8-K · Dec 11, 2025 Risk: medium
  Immunovant, Inc. filed an 8-K on December 11, 2025, reporting an "Other Event" that occurred on December 10, 2025. The filing does not disclose specific details
• Immunovant Reports Leadership and Compensation Changes — 8-K · Nov 21, 2025 Risk: medium
  Immunovant, Inc. filed an 8-K on November 21, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of c
• Immunovant Files 8-K on Financials — 8-K · Nov 10, 2025 Risk: low
  Immunovant, Inc. filed an 8-K on November 10, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits
• Immunovant Files 8-K — 8-K · Sep 3, 2025 Risk: low
  Immunovant, Inc. filed an 8-K on September 3, 2025, reporting on other events and financial statements. The filing does not contain specific material events or
• Immunovant Files 8-K on Shareholder Vote Matters — 8-K · Aug 28, 2025 Risk: low
  Immunovant, Inc. filed an 8-K on August 28, 2025, reporting on a submission of matters to a vote of security holders that occurred on August 27, 2025. The compa
• Immunovant Q1: No Revenue, Focus on Pipeline Development — 10-Q · Aug 11, 2025 Risk: high
  Immunovant, Inc. reported no revenue for the quarter ended June 30, 2025, consistent with its prior-year period, as it remains a clinical-stage biopharmaceutica
• Immunovant Appoints New Director and CMO — 8-K · Jul 29, 2025 Risk: medium
  Immunovant, Inc. announced on July 28, 2025, the departure of director Dr. David M. Roth and the election of Dr. Amy J. Peterson as a new director. The company
• Immunovant Sets August 27 Virtual Annual Meeting, Details Equity Awards — DEF 14A · Jul 9, 2025 Risk: low
  Immunovant, Inc. filed a DEF 14A on July 9, 2025, for its Annual Meeting of Stockholders scheduled for August 27, 2025, indicating a focus on corporate governan
• Immunovant's Net Loss Widens to $304M Amid R&D Push — 10-K · May 29, 2025 Risk: high
  Immunovant, Inc. reported no revenue for the fiscal year ended March 31, 2025, consistent with its clinical-stage biotechnology status. The company posted a net
• Immunovant Announces Board Changes and New CLO — 8-K · Apr 21, 2025 Risk: medium
  Immunovant, Inc. announced on April 18, 2025, a series of significant corporate actions. These include the departure of director Dr. David M. Roth, the election
• Immunovant Files 8-K: Regulatory, Other Events & Exhibits — 8-K · Mar 19, 2025 Risk: low
  Immunovant, Inc. filed an 8-K on March 19, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events
• Immunovant Files 10-Q for Q3 FY2025 — 10-Q · Feb 6, 2025 Risk: medium
  Immunovant, Inc. filed its 10-Q for the period ending December 31, 2024. The filing covers the three and nine months ended December 31, 2024, and compares them
• Immunovant, Inc. Files 8-K — 8-K · Jan 24, 2025 Risk: low
  Immunovant, Inc. filed an 8-K on January 24, 2025, reporting other events and financial statements. The company, formerly known as Health Sciences Acquisitions
• Immunovant Files 8-K for Regulatory Disclosure — 8-K · Jan 14, 2025 Risk: low
  Immunovant, Inc. filed an 8-K on January 14, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain speci
• Immunovant Files 8-K: Material Agreements & Equity Sales — 8-K · Jan 13, 2025 Risk: low
  Immunovant, Inc. filed an 8-K on January 13, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and Regulation FD disc
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Immunovant, Inc. Files 10-Q for Q3 2024 — 10-Q · Nov 7, 2024 Risk: medium
  Immunovant, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its business operat
• Immunovant Files 8-K with Regulatory Updates — 8-K · Sep 9, 2024 Risk: low
  Immunovant, Inc. filed an 8-K on September 9, 2024, to report on various events. The filing includes information related to Regulation FD disclosures, other eve
• Immunovant Files 8-K on Shareholder Vote Matters — 8-K · Aug 13, 2024 Risk: low
  Immunovant, Inc. filed an 8-K on August 13, 2024, reporting on matters submitted to a vote of security holders on August 12, 2024. The filing details the compan
• Immunovant Files 10-Q for Q2 2024 — 10-Q · Aug 6, 2024 Risk: medium
  Immunovant, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations.
• Immunovant Files Definitive Proxy Statement for August Meeting — DEF 14A · Jun 26, 2024 Risk: low
  Immunovant, Inc. filed its definitive proxy statement on June 26, 2024, for its annual meeting on August 12, 2024. The company, formerly known as Health Science
• Immunovant Files 2024 10-K — 10-K · May 29, 2024 Risk: medium
  Immunovant, Inc. filed its 10-K for the fiscal year ending March 31, 2024, reporting on its operations and financial condition. The company, formerly Health Sci
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Immunovant, Inc. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 12, 2024 Risk: low
  Immunovant, Inc. (IMVT) filed a Quarterly Report (10-Q) with the SEC on February 12, 2024. Immunovant, Inc. reported its Q3 2024 financial results. The company'
• FMR LLC Discloses 5.44% Passive Stake in Immunovant (IMVT) — SC 13G · Feb 9, 2024 Risk: low
  FMR LLC, a major investment management firm, and its Chair and CEO, Abigail P. Johnson, have disclosed a significant passive stake in Immunovant, Inc. (IMVT). A
• Immunovant Files 8-K for Regulation FD Disclosure on Jan 9, 2024 — 8-K · Jan 9, 2024
  Immunovant, Inc. filed an 8-K on January 9, 2024, to disclose information under Regulation FD and provide financial statements and exhibits. This filing, under

Related Companies

ARGX

Frequently Asked Questions